Primo-100 100mg/ml 10ml Vial by Para Pharma

Usage

1. Confirm IGF-1, fasting insulin, HOMA-IR, lipid panel, haematocrit, and testosterone baseline via blood test before introducing either compound.
2. Begin HGH alone at 2 IU subcutaneously each morning for the first two weeks to establish tolerability and GH-axis baseline before adding Methenolone Enanthate.
3. From week three, draw 1.5ml of Primo-100 (150mg) twice weekly using a fresh 23–25G needle; administer via intramuscular injection, alternating between glute and lateral quad sites to distribute injection load across the multi-week protocol.
4. At week four, review IGF-1 and HOMA-IR results: if IGF-1 has reached the upper third of the reference range and insulin sensitivity remains acceptable, the HGH dose may be advanced to 3–4 IU/day; Methenolone can be stepped to 400mg/week (2ml per injection twice weekly) if lean-mass tracking justifies it.
5. Inspect each vial before drawing: the solution should be clear to slightly pale-yellow with no particulate matter; if cloudiness or precipitate is visible, do not use and contact the supplier with the lot number from the CoA.
6. Log every injection date, volume drawn, and site used in a cycle journal; cross-reference weekly bodyweight and skinfold measurements against IGF-1 and nitrogen-balance proxies to quantify the additive contribution of the HGH–Methenolone combination objectively.

Warnings

Frequently asked questions

Can Methenolone Enanthate be effectively combined with recombinant HGH in the same cycle?

Yes — Methenolone Enanthate and HGH activate entirely different anabolic pathways (androgen receptor occupancy versus GH/IGF-1/mTOR signalling), so their effects are additive rather than redundant. A typical combination runs 2–4 IU HGH daily alongside 300–400mg Methenolone Enanthate per week, with IGF-1 blood assay at week four confirming GH-axis response while nitrogen retention reflects Methenolone's contribution.

What specific synergies does the HGH and Primobolan combination produce that single-compound use cannot replicate?

HGH drives IGF-1-mediated satellite-cell activation and collagen synthesis, while Methenolone Enanthate sustains AR-driven nitrogen retention and anti-catabolic signalling. Neither compound aromatises meaningfully, so the combined environment promotes lean-tissue accrual and connective-tissue recovery without the subcutaneous fluid accumulation that oestrogen-elevating androgens can introduce alongside HGH.

How should an HGH stack incorporating Primo-100 be planned and monitored?

Establish baseline IGF-1, fasting insulin, HOMA-IR, haematocrit, and lipid values before week one. Introduce HGH at 2 IU daily for two weeks before adding Methenolone Enanthate at 300mg per week. Recheck IGF-1 and HOMA-IR at week four and week eight; adjust HGH dose based on IGF-1 response, and titrate Methenolone in 50mg increments (0.5ml of the 100mg/ml solution) according to lean-mass tracking.

Why does the 100mg/ml concentration of Primo-100 offer a practical advantage over higher-concentration versions in an HGH stack?

At 100mg/ml, each 0.5ml drawn in a standard syringe delivers exactly 50mg — the smallest clinically meaningful dose increment when an athlete is simultaneously adjusting an HGH protocol. Higher-concentration vials compress that resolution; the 100mg/ml format keeps volume-to-dose ratios intuitive and reduces the risk of measurement error during multi-compound administration blocks.

How should Para Pharma Primo-100 10ml vials be stored after the first puncture, and for how long can the vial remain in use?

Store opened vials upright at 15–25 °C, away from direct light and moisture; refrigeration (2–8 °C) is acceptable but not required for oil-based injectables. Most compounding-pharmacy and pharmaceutical industry guidance treats multi-dose vials as usable for up to 28 days after first puncture, provided a fresh sterile needle is used at every withdrawal point to prevent microbial contamination of the remaining solution. (2) angle_used

Manufacturer

Para Pharma's certification framework for injectable steroids rests on three verifiable pillars: GMP-aligned facility qualification, independent lot-release testing, and traceable documentation. Production environments for Primo-100 operate under classified cleanroom conditions, with continuous non-viable particulate monitoring ensuring air quality remains within ISO 5 (Grade A) specifications at every fill point. Before any lot enters the distribution channel, two release tests must clear: HPLC quantification — confirming that active Methenolone Enanthate content matches the labelled 100mg/ml figure within validated acceptance limits — and the LAL (Limulus Amebocyte Lysate) endotoxin assay, which certifies bacterial endotoxin load remains below the threshold defined in the batch-specific release specification. Each passed result is recorded on a lot-numbered Certificate of Analysis that ships with the product, enabling downstream verification at any point in the supply chain. This documentation-centred quality architecture means the athlete using Primo-100 in a precision HGH combination protocol can anchor dosing decisions to instrument-confirmed potency data rather than label trust alone.